New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

PatentVest released a Pulse report (May 8, 2026) mapping the emerging triple-agonist obesity race and an intensifying patent battle shaping the post-GLP-1 market.

Rhea-AI Summary

PatentVest released a Pulse report (May 8, 2026) mapping the emerging triple-agonist obesity race and an intensifying patent battle shaping the post-GLP-1 market.

Key points: identification of 27 global triple-agonist programs, Eli Lilly’s retatrutide cited for near‑bariatric efficacy, rising importance of receptor‑ratio engineering, delivery platforms, formulation control, and latent IP holdings from multiple firms that could reshape future competition.

Positive

• 27 triple-agonist programs identified worldwide
• Retatrutide highlighted as a leading triple-agonist with near-bariatric efficacy
• China accounts for a significant share of development activity

Negative

• IP competition shifting from discovery to delivery, formulation, and receptor-ratio claims
• Latent IP positions from companies without visible clinical programs could constrain market entrants
• Complex patents on delivery and formulation may prolong exclusivity disputes

Argus May 8 session

+8.16% close to close Open Argus

Details

News Market Reaction – MDBH

On May 8, the day this news came out, MDBH closed 8.16% above the previous close.

Data tracked by StockTitan Argus for the May 8 session.

Key Figures

Triple-agonist programs: 27 programs

Triple-agonist programs

27 programs

Global triple-agonist pipeline mapped in PatentVest report

Historical Context

5 past events · Latest: Apr 29

5 events

1. Apr 29

   Obesity IP report

   24h Move

   -3.0%

   Retatrutide report mapping obesity pipeline and highlighting Sanofi’s large IP position.

2. Mar 31

   Full-year update

   24h Move

   +7.0%

   2025 update detailing asset stakes, cash levels, expenses, and spin-out strategy.

3. Mar 31

   Amylin race report

   24h Move

   +1.7%

   Pulse report on amylin obesity programs and $19B in related deal value.

4. Mar 30

   AI patent article

   24h Move

   -1.7%

   Legal insights piece on AI patenting strategy and USPTO guidance implications.

5. Mar 30

   Strategic partnership

   24h Move

   -1.7%

   Life Seal Vascular partnership with equity taken for IP intelligence services.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

triple-agonist, glp-1, gip, glucagon receptor, +3 more

7 terms

triple-agonist medical

"Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline"

A triple-agonist is a drug designed to stimulate three different biological targets or pathways at once, similar to a single key that can open three different locks. For investors, this matters because combining multiple effects in one medicine can increase potential benefits—like better symptom control or weight loss—but also raises development complexity, safety and regulatory risk, and manufacturing or pricing challenges that can amplify both upside and downside for a company.

glp-1 medical

"as the market transitions beyond first-generation GLP-1 therapies"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

gip medical

"driven by the convergence of GLP-1, GIP, and glucagon receptor targeting"

GIP commonly stands for Global Infrastructure Partners, a private investment firm that buys and manages large physical assets such as airports, power plants, toll roads and pipelines. Investors pay attention because when GIP acquires, invests in, or sells such assets it can alter cash flow, debt levels and long-term plans for those businesses—like a new landlord changing rents or making upgrades—affecting revenue, dividends and risk for shareholders and creditors.

glucagon receptor medical

"driven by the convergence of GLP-1, GIP, and glucagon receptor targeting"

A glucagon receptor is a protein on the surface of certain cells that acts like a lock for the hormone glucagon, which is a key that signals the body to release stored sugar into the bloodstream. Investors care because drugs that block or activate this receptor can change blood sugar, weight and metabolism—so success or failure in developing such drugs can materially affect a biotech company’s value and market prospects.

receptor-ratio engineering medical

"intellectual property strategy, receptor-ratio engineering, and delivery platforms may determine"

Receptor-ratio engineering is a lab technique that adjusts how strongly a therapeutic molecule, like a drug or antibody, binds to multiple cell receptors by changing their relative targeting strengths. Think of it like tuning the balance on a stereo so one speaker plays louder than the other to get the desired sound; for investors, this tuning can improve a therapy’s effectiveness and reduce side effects, which influences clinical success, development costs, and commercial value.

freedom-to-operate regulatory

"platform design, formulation, and freedom-to-operate strategies"

Freedom-to-operate is a legal assessment that checks whether a company can make, sell, or use a product or technology without violating someone else’s patents or other IP rights. For investors it matters because a negative finding can lead to costly lawsuits, licensing fees, production delays, or forced changes to a product — like discovering a road to market is blocked and you must pay to pass or find a new route.

intellectual property regulatory

"PatentVest’s analysis suggests that the next stage of competition will extend beyond clinical outcomes into intellectual property positioning"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

· Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.

· PatentVest’s report reveals how intellectual property strategy, receptor-ratio engineering, and delivery platforms may determine the next leaders in obesity therapeutics.

DALLAS, TX, May 08, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, “The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.” This comprehensive study provides a strategic analysis of the rapidly evolving obesity-drug landscape as the market transitions beyond first-generation GLP-1 therapies.

The release comes as Eli Lilly and Company’s retatrutide has emerged as a leading triple-agonist candidate, delivering results that approach bariatric-surgery-level efficacy and signaling a new phase in obesity therapeutics. PatentVest’s analysis suggests that the next stage of competition will extend beyond clinical outcomes into intellectual property positioning, delivery systems, and long-term market control.

The report highlights the structural shift underway in obesity drug development, driven by the convergence of GLP-1, GIP, and glucagon receptor targeting, as well as the growing importance of platform design, formulation, and freedom-to-operate strategies. Key findings include:

· Competitive Landscape: Insights into industry leaders including Eli Lilly and Company, Novo Nordisk, Pfizer, Roche, and Sanofi, alongside emerging players such as Hanmi Pharmaceutical, Innovent Biologics, Zealand Pharma, Septerna, Kailera Therapeutics, Metsera, Ascletis Pharma, Rani Therapeutics, Structure Therapeutics, and Viking Therapeutics, all competing to define the next generation of obesity therapeutics.

· Global Pipeline Expansion: Identification of 27 triple-agonist programs, with China accounting for a significant share of development activity, signaling a shift in global innovation dynamics and potential future licensing activity.

· Intellectual Property Dynamics: Patent analysis reveals a transition from receptor discovery to receptor-ratio engineering, formulation control, delivery systems, and method-of-use claims as key drivers of long-term competitive advantage.

· Strategic Positioning: Findings suggest that companies without visible clinical programs, including Sanofi, may hold significant latent IP positions that could influence the future structure of the market.

“Obesity drug development is entering a new phase,” said Will Rosellini, Chief IP Officer at PatentVest. “The first GLP-1 era was about proving these therapies could deliver meaningful weight loss. The next phase will be defined by who controls the intellectual property, delivery platforms, and receptor configurations that shape the market after retatrutide.”

The PatentVest Pulse report is now available for download on the PatentVest website: https://insights.patentvest.com/the-last-20.

For more information or inquiries, please contact info@patentvest.com.

The insights and analysis presented in this report are derived from PatentVest’s proprietary IP intelligence platform, which integrates patent data, clinical pipeline analysis, and strategic market mapping to identify emerging trends and competitive positioning across biotechnology sectors.

About PatentVest

PatentVest is the first integrated IP intelligence, strategy, and law firm built for companies where patents drive enterprise value. The firm pairs seasoned IP counsel with a dedicated analyst team and a proprietary technology platform to deliver portfolio strategy, diligence, and prosecution work with the rigor of Big Law and the speed modern innovators require. PatentVest Pulse, the firm's research series, maps the competitive and IP landscapes of frontier technology sectors, from brain-computer interfaces and humanoid robotics to AI infrastructure and next-generation therapeutics, giving investors, boards, and operators a clear view of who owns the innovation that will define each market. PatentVest is a division of MDB Capital Holdings (Nasdaq: MDBH). Learn more at patentvest.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PatentVest report say about Eli Lilly's retatrutide and MDBH on May 8, 2026?

Retatrutide is identified as a leading triple-agonist approaching bariatric-level weight loss, signaling a new market phase. According to PatentVest, this shifts competition toward intellectual property, delivery platforms, and receptor-ratio engineering that will influence post-GLP-1 leadership.

How many triple-agonist programs did PatentVest identify and what does that mean for MDBH investors?

PatentVest identified 27 global triple-agonist programs, showing rapid pipeline expansion. According to PatentVest, this broad development base increases competitive intensity and raises the strategic value of IP and platform positioning for companies like those tracked under MDBH.

What intellectual property trends did the PatentVest Pulse report highlight relevant to MDBH?

The report highlights a shift from receptor discovery to receptor-ratio engineering, formulation control, and delivery-system claims. According to PatentVest, these IP trends will be key determinants of long-term market control and competitive advantage.

Does the PatentVest report identify geographic hotspots in triple-agonist development affecting MDBH?

Yes. The report notes a significant share of development activity in China, indicating a geographic shift in innovation. According to PatentVest, this could affect future licensing, partnerships, and competitive dynamics relevant to MDBH stakeholders.

How might latent IP holdings from firms without clinical programs impact MDBH and the obesity market?

Latent IP positions could influence market structure by restricting freedom to operate or enabling licensing leverage. According to PatentVest, companies without visible clinical programs may still hold patents that materially affect commercialization and competition.